Treatment of gynecological malignancies with biologically active peptides
AssigneeMagainin Pharmaceuticals Inc.
InventorsLeonard S. Jacob, W. Lee Maloy, Margaret A. Baker
Life of this patent
Estimating the term…
Abstract
A process for treating a gynecological malignancy in a host which comprises administering to the host at least one biologically active amphiphilic peptide or protein. The peptide or protein may be administered intralesionally, intravenously, or intraperitoneally, whereby the peptide or protein may inhibit, prevent, or destroy the growth of the gynecological malignancy, such as an ovarian cancer, uterine cancer, or cervical cancer.
Claims6
A process for inhibiting the growth of ovarian cancer cells in a mammalian host, comprising:
- administering at least one biologically active magainin peptide in an amount sufficient to inhibit the growth of ovarian cancer cells.
A process for inhibiting the growth of ovarian cancer cells in a mammalian host, comprising:
- administering at least one biologically active amphiphilic ion channel-forming peptide selected from the group consisting of SEQ ID NO 116 and SEQ ID NO 27 in an amount sufficient to inhibit the growth of ovarian cancer cells.
Dependencies are inferred from the claim text.